FibroBiologics, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of FibroBiologics, Inc. Common Stock generated cash of -$6,401,000, which is less than the previous year. Cash used in financing activities reached the amount of $13,793,000 last year. Net change in cash is therefore $6,897,000.
Cash Flow
| 2022 | -4.06M | 0 | 5.92M |
|---|---|---|---|
| 2023 | -6.40M | -495K | 13.79M |
FBLG Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 2.26M | 407K |
Operating activities | ||
Net income | -16.48M | -5.12M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 437K | 94K |
Stock-based compensation expense | 1.76M | 265K |
| Deferred income tax benefit | 1.76M | 265K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 141K | 525K |
Cash generated by operating activities | -6.40M | -4.06M |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | -495K | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -495K | 0 |
Financing activities | ||
Common Stock Issued | 16.13M | 2.15M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | 3.77M |
Cash used in financing activities | 13.79M | 5.92M |
Net Change In Cash | 6.89M | 1.85M |
Cash at end of period | 9.16M | 2.26M |